Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents-Reference-Cited by-同舟云学术

Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents

Published:2014-08-06 Issue:6 Volume:35 Page:341-352
ISSN:0142-2782
Container-title:Biopharmaceutics & Drug Disposition
language:en
Short-container-title:Biopharm. Drug Dispos.

Author:

Johnson Trevor N.¹,Zhou Diansong²,Bui Khanh H.²

Affiliation:

1. Simcyp Ltd; Sheffield UK

2. Quantitative Clinical Pharmacology; AstraZeneca PLC; Wilmington Delaware USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/bdd.1899/fullpdf

Reference26 articles.

1. AstraZeneca Seroquel® (quetiapine fumarate) tablets/US prescribing information 2008

2. AstraZeneca PLC Seroquel XR (quetiapine fumarate) extended-release tablets/US prescribing information 2011

3. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic;DeVane;Clin Pharmacokinet,2001

4. Steady state pharmacokinetic, safety and tolerability profiles of quetiapine, norquetiapine and other quetiapine metabolites in pediatric and adult patients with psychotic disorders;Winter;J Child Adolesc Psychopharmacol,2008

5. Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology;Rostami-Hodjegan;Clin Pharmacol Ther,2012

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple Adverse Reactions Associated With the Use of Second-Generation Antipsychotics in People With Alzheimer’s Disease: A Pharmacovigilance Analysis Based on the FDA Adverse Event Reporting System;Annals of Pharmacotherapy;2024-08-20

2. Population Pharmacokinetic Modeling and Stochastic Simulations to Support Pediatric Dose Selection of Pimavanserin;The Journal of Clinical Pharmacology;2023-08-17

3. Use of Developmental Midazolam and 1-Hydroxymidazolam Data with Pediatric Physiologically Based Modeling to Assess Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyl Transferase 2B4 Ontogeny In Vivo;Drug Metabolism and Disposition;2023-05-11

4. Approaches of formulation bridging in support of orally administered drug product development;International Journal of Pharmaceutics;2022-12

5. Another Step Toward Qualification of Pediatric Physiologically Based Pharmacokinetic Models to Facilitate Inclusivity and Diversity in Pediatric Clinical Studies;Clinical Pharmacology & Therapeutics;2022-11-17